Jul 2026· Circulation. Population health and outcomes· Vol 19, pp.
e013035
· 0 citations· 19 references
Medicine
TL;DR
Distinct BP phenotypes beyond absolute BP thresholds confer differential risks for CKO, and interventional studies are needed to evaluate strategies targeting combined systolic-diastolic phenotypes to reduce CKO risk.
Abstract
Background
Hypertension is a leading cause of cardio-kidney outcomes (CKO). However, distinct blood pressure (BP) phenotypes and their effect on CKO remain underexplored. This study aimed to evaluate the independent contributions of BP phenotypes to CKO.
Methods
This prospective, population-based study included UK Biobank participants enrolled between 2006 and 2010 with baseline systolic BP ≥90 mm Hg and estimated glomerular filtration rate ≥60 mL/min per 1.73 m2, excluding those with prior chronic kidney disease and cardiovascular disease. Five BP phenotypes were constructed based on the 2017 American Heart Association hypertension criteria (≥130/80 mm Hg): normotension, systolic-diastolic hypertension, isolated systolic hypertension, isolated diastolic hypertension, and isolated low diastolic BP. The primary outcome was CKO, a composite of incident chronic kidney disease, 3-point major cardiovascular events, and all-cause mortality based on the International Classification of Diseases and Office of Population Censuses and Surveys Classification of Interventions and Procedures, Version 4, codes. Associations between BP phenotypes and CKO were evaluated using multivariable Cox proportional hazards models adjusted for demographic, lifestyle, and clinical covariates.
Results
Among 322 328 participants (mean age, 55.8±8.1 years; 42.5% men), 61 918 (19.2%) had normotension, 159 853 (49.6%) had systolic-diastolic hypertension, 43 939 (13.6%) had isolated systolic hypertension, 28 169 (8.7%) had isolated diastolic hypertension, and 28 339 (8.8%) had isolated low diastolic BP. Over a median follow-up of 13.6 years, 32 440 CKO events occurred. All BP phenotypes were associated with an increased CKO risk compared with normotension: isolated systolic hypertension (hazard ratio, 1.22 [95% CI, 1.17-1.27]), systolic-diastolic hypertension (hazard ratio, 1.21 [95% CI, 1.16-1.25]), isolated diastolic hypertension (hazard ratio, 1.11 [95% CI, 1.05-1.17]), and isolated low diastolic BP (hazard ratio, 1.10 [95% CI, 1.05-1.17]).
Conclusions
Distinct BP phenotypes beyond absolute BP thresholds confer differential risks for CKO. Interventional studies are needed to evaluate strategies targeting combined systolic-diastolic phenotypes to reduce CKO risk.
Elevated BP as a major modifiable risk factor for kidney failure mortality, CKD, and albuminuria is highlighted in this large prospective study in Mexican adults.
Doreen Zhu, P. Kuri-Morales, Rachel Wade et al.· American Journal of Kidney D...· 0 citations
The prevalence of hypertension-associated cardiac damage was higher in WCHT and in MHT compared to SNT and WCHT should be considered when assessing cardiovascular risk, and BP should be measured both in the office and at home when diagnosing and monitoring hypertension.
M. Randjelovic, M. Wijkman, Karin Festin et al.· Journal of Hypertension· 0 citations
This transparent, rule-based classification summarized differences in recorded mortality and cardiovascular outcomes in T2D but should be interpreted as a descriptive framework rather than a validated prediction tool.
Jianzhong Ding, Laixi Kong, Rui Zhou et al.· Diabetes Research and Clinic...· 0 citations
In nephrology-referred patients with advanced CKD, achieved SBP around 120–<130 mmHg (near 125 mmHg) was associated with the lowest cardiovascular and mortality risk, while SBP ≥140 mmHg, especially ≥160 mmHg, was consistently associated with higher MACE risk.
Ehab Al-sodany, K. Szummer, Joakim Österman et al.· Clinical Kidney Journal· 0 citations
A U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.
Yuta Suzuki, Masachika Nishikawa, Hidehiro Kaneko et al.· Hypertension Research· 0 citations
UACR testing was underutilized among patients with diabetes and hypertension, and consistent screening could have identified individuals who would benefit from guideline directed antiproteinuric therapies.
Jian Roushani, Sachin V. Pasricha, L. Dubrofsky et al.· Canadian Journal of Diabetes· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.